Article
Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles.
Toxicology and applied pharmacology - 1 May 2023
Gong Fei, Hu Huihui, Ouyang Ying, Liao Zheng-Zheng, Kong Ying, Hu Jin-Fang, He Hua, Zhou Ying
Abstract excerpt
The drug-drug interactions (DDIs) between tacrolimus and voriconazole are highly variable among individuals. We aimed to develop a physiologically based pharmacokinetic (PBPK) model to predict the DDIs in people with different CYP3A5 and CYP2C19 alleles. First, pharmacokinetic data of humans receiving tacrolimus with or without voriconazole from the literature were used to construct and validate the PBPK model....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
